InterMune's (ITMN) Pirfenidone drug met the primary goal of a Phase III trial by significantly reducing the progression of idiopathic pulmonary fibrosis (IPF) or mortality.
"IPF is an irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis (scarring) in the lungs, which hinders the ability of lungs to absorb oxygen," InterMune explains. IPF's five-year survival rate is 20-40%.
Pirfenidone also met secondary endpoints with improvements in six-minute walk tests and progression-free survival.
InterMune now plans to resubmit an application for FDA authorization of Pirfenidone.
Trading in the firm's shares has been halted. (PR)